Cargando…
FDG-PET/CT based response-adapted treatment
It has been shown that [(18)F]fluorodeoxyglucose (FDG)-positron emission tomography (PET) provides robust and reproducible data for early metabolic response assessment in various malignancies. This led to the initiation of several prospective multicenter trials in malignant lymphoma and adenocarcino...
Autores principales: | de Geus-Oei, Lioe-Fee, Vriens, Dennis, Arens, Anne I.J., Hutchings, Martin, Oyen, Wim J.G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
e-Med
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460598/ https://www.ncbi.nlm.nih.gov/pubmed/23023063 http://dx.doi.org/10.1102/1470-7330.2012.9006 |
Ejemplares similares
-
Multiparametric PET/CT in oncology
por: Singh, Dalveer, et al.
Publicado: (2012) -
Should positron emission tomography/computed tomography be the first rather than the last test performed in the assessment of cancer?
por: Hicks, Rodney J.
Publicado: (2012) -
Predictive and prognostic value of FDG-PET
por: de Geus-Oei, Lioe-Fee, et al.
Publicado: (2008) -
Methodological considerations in quantification of oncological FDG PET studies
por: Vriens, Dennis, et al.
Publicado: (2009) -
FDG-PET/CT in lymphoma
por: D'souza, Maria M, et al.
Publicado: (2013)